Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has appointed Dr. Reshma Rangwala as Chief Medical Officer, effective mid-April 2022. Dr. Rangwala brings over a decade of oncology experience, previously serving as CMO at Aravive and holding significant roles at Genmab and Merck. The company also announced the departure of co-founders Dr. Sharon Shacham and Dr. Michael Kauffman on May 31, 2022, although Dr. Shacham will remain on the Scientific Advisory Board. Karyopharm aims to accelerate its clinical development programs for its key therapeutic assets, XPOVIO and eltanexor.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the upcoming presentations of results from the Phase 3 SIENDO study of selinexor for advanced or recurrent endometrial cancer at the ESMO Virtual Plenary on March 17, 2022, and the SGO 2022 Annual Meeting on Women's Cancer from March 18-21, 2022. The SIENDO study is a multicenter, randomized trial involving 263 patients, aiming to demonstrate improved progression-free survival with selinexor maintenance therapy compared to placebo. The study represents an important step, as there are currently no approved maintenance therapies for this cancer type.
Karyopharm Therapeutics (Nasdaq: KPTI) announces the appointment of Elhan Webb as Senior Vice President of Investor Relations, effective March 14, 2022. Webb brings over 20 years of experience in investor relations and business development, having held roles at Rubius Therapeutics and Radius Health. CEO Richard Paulson emphasized her expertise in building investor relations to enhance Karyopharm's visibility in the market. The company is known for its lead compound, XPOVIO®, which is approved in multiple oncology indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced its senior management will engage in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 a.m. ET in Miami, Florida. This event highlights Karyopharm's pioneering role in developing cancer therapies, particularly with its lead product, XPOVIO® (selinexor), which is approved for multiple oncology indications.
Investors can access a live webcast of this chat and related slides via the company's investor site, with a replay available for 90 days post-event.
Karyopharm Therapeutics (KPTI) provided an update on its discussions with the FDA regarding its supplemental New Drug Application (sNDA) for selinexor, intended for advanced endometrial cancer. The FDA indicated that existing SIENDO study results might not justify an sNDA approval. Differing views on the study's clinical significance led to plans for a new randomized clinical trial focusing on p53 wild-type patients, with top-line data expected in H1 2024. The SIENDO study results will be presented at upcoming oncology conferences in March 2022.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on February 28, 2022, the approval of stock options for 168,500 shares and 112,200 restricted stock units (RSUs) to nine new employees. These awards are part of the 2022 Inducement Stock Incentive Plan and serve as an employment inducement per Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $10.33, vesting over four years, with specific conditions for immediate exercise upon a change in control or termination for good reason.
Karyopharm Therapeutics (Nasdaq: KPTI) announced key changes in its clinical leadership team on February 22, 2022. Patricia Judson, M.D., joins as Senior VP of Medical Strategy, and Stuart Poulton as Senior VP of Strategy and Portfolio Management. Jatin Shah, M.D., has stepped down as Chief Medical Officer but will remain in an advisory role. Richard Paulson, CEO, highlighted that the new leaders bring extensive oncology and pharmaceutical experience, which will aid the company in advancing its drug pipeline addressing significant unmet medical needs.
Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast will be available in the Investor section of their website, with replays accessible for 90 days. Karyopharm specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, including its approved drug XPOVIO®. The company's pipeline targets multiple high unmet need cancer indications.
Karyopharm Therapeutics (Nasdaq: KPTI) reported strong financial results for Q4 2021, with net product revenue of $29.8 million, a 47% increase year-over-year. Total revenue for 2021 reached $209.8 million, up from $108.1 million in 2020. They achieved significant milestones, including a commercialization partnership with Menarini and positive data from the SIENDO study on selinexor. However, the company reported a net loss of $124.1 million for 2021. For 2022, Karyopharm expects XPOVIO revenue between $135 million and $145 million.
Karyopharm Therapeutics (Nasdaq: KPTI) reported positive results from its Phase 3 SIENDO study on selinexor for patients with advanced or recurrent endometrial cancer. The study involved 263 patients and achieved a median progression-free survival (PFS) of 5.7 months with selinexor, compared to 3.8 months for placebo, marking a 50% improvement. The drug showed a 30% reduction in disease progression risk. Particularly, patients with wild-type p53 saw a median PFS of 13.7 months. Karyopharm plans to submit a supplemental New Drug Application to the FDA in H1 2022.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
